HC Wainwright Has Optimistic Outlook of LYEL Q1 Earnings

Lyell Immunopharma, Inc. (NASDAQ:LYEL) – Research analysts at HC Wainwright increased their Q1 2025 EPS estimates for Lyell Immunopharma in a report issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.17) per share for the quarter, up from their prior estimate of ($0.20). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%.

Lyell Immunopharma Price Performance

Shares of NASDAQ LYEL opened at $0.59 on Monday. The company has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.91. The firm has a market cap of $172.83 million, a PE ratio of -0.74 and a beta of -0.41. Lyell Immunopharma has a 1 year low of $0.51 and a 1 year high of $3.15.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its holdings in Lyell Immunopharma by 312.7% during the 3rd quarter. Barclays PLC now owns 240,615 shares of the company’s stock worth $332,000 after purchasing an additional 182,315 shares during the last quarter. SG Americas Securities LLC raised its holdings in Lyell Immunopharma by 102.8% during the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after purchasing an additional 59,182 shares during the last quarter. Jane Street Group LLC raised its holdings in Lyell Immunopharma by 63.7% during the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock worth $397,000 after purchasing an additional 111,917 shares during the last quarter. State Street Corp raised its holdings in Lyell Immunopharma by 1.9% during the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Lyell Immunopharma during the 3rd quarter worth approximately $52,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.